Efficacy and Tolerability of DispersinB Acne Cleanser in the Treatment of Mild to Moderate Acne V… (NCT06729450) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Efficacy and Tolerability of DispersinB Acne Cleanser in the Treatment of Mild to Moderate Acne Vulgaris
United States24 participantsStarted 2026-01-30
Plain-language summary
This is a single-center study using intra-individual comparison (right half-face versus left half-face) to evaluate the efficacy and tolerability of DispersinB Acne Cleanser for treatment of acne in adults. An initial sample size of 24 subjects is planned to be randomized in order to provide proof of concept efficacy and tolerability of the product.
The main questions it aims to answer are:
1. Percent of subjects rated "Clear" and "Almost Clear" on a 5-point scale 0=clear; 4=severe) at 12 weeks
2. Change in inflammatory and noninflammatory lesion count per half-face at 12 weeks
Researchers will compare each half-face:
* one half facial wash with DispersinB Acne Cleanser and 4% Benzoyl Peroxide.
* one half facial wash with 4% Benzoyl Peroxide only
Subjects will use the DispersinB Acne Cleanser on the assigned facial side for 5 minutes and then will use the provided 4% Benzoyl peroxide facial wash to wash entire face for daily (evening) use.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Male or female subject aged 18 years or older, at screening visit.
. Subject with clinical diagnosis of acne vulgaris on the face as defined by Investigator's Global Assessment (IGA) score of 2 (Mild) or 3 (Moderate), with the same score on both sides of the face.
. Subject with a symmetrical number of lesions on the whole face.
. The subject is a female of childbearing potential is willing to undergo UPTs throughout the study.
. Subject having read, understood, and signed the approved Informed Consent Form (ICF) prior to any participation in the study.
. Subject agrees and is able to comply with all time commitments and procedural requirements of the protocol.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Success rate per half-face
Timeframe: Baseline to week 12
2
Change in inflammatory and noninflammatory lesion count
. Subject agrees to having facial photographs taken and verified by the subject signing an approved photography ICF.
. Subject is informed of terms pertaining to personal information protection and privacy and is willing to share personal information and data, as verified by signing a written authorization form.
Exclusion criteria
. Subject with acne types other than acne vulgaris.
. Subject with dermal conditions on the face that may interfere with study assessments in the opinion of the investigator (tattoo, skin abrasion, eczema, sun burn, scars, large nevi, etc.).
. Subject with excessive facial hair that would interfere with study assessments, as judged by the investigator.
. Pregnant women (positive urine pregnancy test at screening or baseline) or women planning pregnancy during the study.
. Subjects taking Vitamin A supplements in excess of the recommended daily allowance (4000-5000 IU; no washout period is required).
. Subject with a washout period for topical treatment or procedures on the face less than: